Physicochemical, Crystallographic, Thermal, and Spectroscopic Behavior of Crystalline and X-ray Amorphous Ciclesonide

Feth, Martin P.; Volz, Jürgen; Heß, Ursula; Sturm, E.; Hummel, Rolf‐Peter

doi:10.1002/jps.21223

Cited by 22 publications

(17 citation statements)

References 33 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DSC was found more accurate and sensitive than FT-Raman spectroscopy [56]. Beclomethasone dipropionate clathrate formation with trichloromonofluoromethane for being used in a suspension metered dose inhaler was characterized by XRPD, X-ray photoelectron spectroscopy, scanning electron microscopy and DSC [57].…”

Section: Solid Phase Characterizationmentioning

confidence: 99%

Advances in the analysis of steroid hormone drugs in pharmaceuticals and environmental samples (2004–2010)

Gǒrög

2011

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Section: Solid Phase Characterizationmentioning

confidence: 99%

Advances in the analysis of steroid hormone drugs in pharmaceuticals and environmental samples (2004–2010)

Gǒrög

2011

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…In another case, dissolution of crystalline and amorphous ciclesonide was studied (Feth et al 2008). Crystalline and amorphous ciclesonide exhibit the same saturation solubility (Feth et al 2008). For the crystalline ciclesonide, within the first 60 min of dissolution, the concentration measured (50 mg/L) was significantly lower than its saturation solubility (90.1 ± 2.2 mg/L).…”

Section: Between Amorphous and Crystalline Phasementioning

confidence: 99%

“…Analysis of the remaining sample after the dissolution experiment confirmed that the sample surface had converted to the dihydrate (crystalline form) during dissolution ). In another case, dissolution of crystalline and amorphous ciclesonide was studied (Feth et al 2008). Crystalline and amorphous ciclesonide exhibit the same saturation solubility (Feth et al 2008).…”

Section: Between Amorphous and Crystalline Phasementioning

confidence: 99%

Amorphous Solid Dispersions

Shah¹,

Sandhu²,

Choi³

et al. 2014

Advances in Delivery Science and Technology

112

View full text Add to dashboard Cite

“…The crystal growth dimension, m, is either one, two, or three, corresponding to rod-like (unidimensional), disk-like (bidimensional), or spherulitic (tridimensional) crystal habits, respectively. 25,26) The reaction order, n, is equal to m for instantaneous nucleation or to m+1 for sporadic nucleation. Figure 2 shows the microscopic aspects of phenytoin crystals.…”

Section: Fig 1 Accumulation Curves Of Phenytoin Crystals After Miximentioning

confidence: 99%

Contribution of Glucose to Crystallization of Phenytoin in Injectable Dosage Form by Dilution with Infusion Fluids

Onuki

Hasegawa

Ikegami-Kawai

et al. 2014

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

The crystallization of phenytoin occurring after its dilution with infusion fluid is a major concern in the clinical use of injectable phenytoin. To gain further understanding of the crystallization, this study assessed details of the involvement of glucose in this action. For sample preparation, phenytoin crystals were created by diluting the injectable phenytoin with infusion fluids with different glucose concentrations at different temperature, and then the characteristics of the crystallization (e.g., crystal size in the long direction, accumulated amount over 24 h, and crystallization rate constant) were measured. Results of the analysis of variance indicated that the glucose concentration and temperature had significant impacts on the crystallization. The mode of action of the glucose concentration was suggested to be different from that of the incubation temperature. This study also examined the molecular mobility of components (i.e., glucose, propylene glycol, phenytoin) in the admixtures using diffusion NMR techniques. The findings will provide valuable information for the clinical use of injectable phenytoin.

show abstract

Physicochemical, Crystallographic, Thermal, and Spectroscopic Behavior of Crystalline and X-ray Amorphous Ciclesonide

Cited by 22 publications

References 33 publications

Advances in the analysis of steroid hormone drugs in pharmaceuticals and environmental samples (2004–2010)

Advances in the analysis of steroid hormone drugs in pharmaceuticals and environmental samples (2004–2010)

Amorphous Solid Dispersions

Contribution of Glucose to Crystallization of Phenytoin in Injectable Dosage Form by Dilution with Infusion Fluids

Contact Info

Product

Resources

About